Daniel Passeri - Mar 21, 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 21, 2025
Transactions value $
$0
Form type
4
Date filed
3/25/2025, 04:00 PM
Previous filing
Dec 18, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +450K $0.00 450K Mar 21, 2025 Common Stock 450K $0.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.